Cyclophosphamide after transplant for blood cancer without sibling donor
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer diagnosis that needs a stem cell transplant
- You do not have a matched brother or sister donor, but you do have a matched unrelated donor (9/10 or 10/10 match)
- Your leukemia is not in an active state—your bone marrow blasts are 5% or less
- You do not have a serious, hard-to-treat lymph/immune cancer (chemorefractory lymphoproliferative disease)
- You do not have a serious, uncontrolled infection right now
- Your health tests and history must allow this study medicine, including no past similar donor stem cell transplant and no reason you cannot take cyclophosphamide or ATG
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
This trial tests whether a lower dose of a common drug (cyclophosphamide) after transplant can prevent graft-versus-host disease (a complication where donor cells attack your body) just as well as the standard dose. It also uses another medicine (anti-thymocyte globulin) after the transplant to help protect you.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This early-phase study tests giving cyclophosphamide after a specific type of stem cell transplant (haploidentical) in people age 65 and older. It aims to improve transplant safety and outcomes by adjusting medicine given after the graft is placed.
This study looks at whether giving a medicine called cyclophosphamide after a stem cell transplant helps work better and for whom. You may be eligible if you are planning a certain type of transplant and your team plans to give post-transplant cyclophosphamide.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Hear when a new Bone Marrow Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.